Trial Profile
Pilot Study Evaluating the Expression of ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase 0
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 09 Mar 2017 Status changed from discontinued to withdrawn prior to enrolment.
- 20 Jul 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 21 Oct 2009 New trial record